Omega Healthcare Investors Inc.
OHI
$46.61
-0.30%
Omega Healthcare Investors Inc. is a real estate investment trust (REIT) that specializes in healthcare-related real estate, primarily skilled nursing facilities and assisted living facilities across the U.S., U.K., and Canada. As one of the largest healthcare REITs, it differentiates itself through its focus on skilled nursing and its role as a capital partner to third-party operators. The current investor narrative centers on the company's recovery from pandemic-era challenges, with recent quarters showing strong revenue growth and improved occupancy, while investors debate the sustainability of its dividend and the impact of rising interest rates on its cost of capital.…
OHI
Omega Healthcare Investors Inc.
$46.61
Related headlines
Investment Opinion: Should I buy OHI Today?
Based on the analysis, OHI is rated a 'Buy' with a thesis that the company's strong revenue growth, high margins, and solid balance sheet support a sustainable dividend and moderate upside. The analyst consensus is a 'Buy' with an average price target of $51.94, implying an 11.4% upside. The stock is suitable for income-focused investors seeking a high yield with moderate growth potential.
Sign up to view all
OHI 12-Month Price Forecast
The AI assessment is neutral with medium confidence. OHI's fundamentals are solid, with strong revenue growth and high margins, but the stock faces headwinds from interest rate sensitivity and a high payout ratio. The analyst consensus is bullish, but the recent downgrades and underperformance relative to the market suggest caution. The stance would be upgraded to bullish if the company demonstrates consistent dividend coverage and revenue growth above 15%, or if interest rates decline. It would be downgraded to bearish if the dividend is cut or if revenue growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Omega Healthcare Investors Inc.'s 12-month outlook, with a consensus price target around $51.94 and implied upside of +11.4% versus the current price.
Average Target
$51.94
0 analysts
Implied Upside
+11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$45 - $61
Analyst target range
Analyst coverage is robust, with 18 analysts covering OHI, and the consensus recommendation is a 'Buy' with a mean rating of 2.4 (where 1 is Strong Buy and 5 is Sell). The average price target is $51.94, implying an upside of 11.4% from the current price of $46.61. The distribution of ratings is not provided, but the recommendation mean suggests a bullish tilt. The target price range is $45.00 to $61.00, with the low target implying a downside of 3.5% and the high target implying an upside of 30.9%. The wide spread of $16.00 indicates significant uncertainty among analysts, which is typical for REITs sensitive to interest rates. Recent ratings actions show a mix: Barclays downgraded to Underweight in July 2026, while B of A Securities downgraded to Underperform in April 2026, but UBS and Citigroup maintain Buy ratings, reflecting divergent views on the stock's prospects.
Bulls vs Bears: OHI Investment Factors
Omega Healthcare Investors presents a mixed picture. On the bull side, the company shows strong revenue growth, high margins, a solid balance sheet, and an attractive dividend yield. On the bear side, the high payout ratio, underperformance relative to the market, and sensitivity to interest rates are significant concerns. Currently, the bull case has slightly stronger evidence, given the robust operational performance and analyst support. The most critical tension is the sustainability of the dividend: if earnings growth continues and interest rates remain stable, the stock could re-rate higher; however, any cut to the dividend or a spike in rates would severely undermine the investment thesis.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 16.68% YoY to $322.96M, driven by acquisitions and rent escalations. This marks a consistent upward trend from $252.75M in Q2 2024, indicating robust operational momentum.
- High Profitability Margins: Gross margin stands at 97.21% and net margin at 46.77% for Q1 2026, reflecting the efficiency of the net-lease REIT model. These margins are well above the industry average, showcasing strong cost control.
- Solid Balance Sheet: Debt-to-equity ratio of 0.82 and current ratio of 3.46 indicate a healthy financial position. The company generated $218.90M in operating cash flow and $210.14M in free cash flow in Q1 2026, comfortably covering its dividend.
- Attractive Dividend Yield: With a dividend yield of 5.94%, OHI offers a compelling income stream. The free cash flow coverage of the dividend (payout ratio of 132% based on net income but adequate FCF coverage) suggests sustainability.
Bearish
- High Payout Ratio: The payout ratio of 132.24% based on net income is concerning, as it suggests the dividend is not fully covered by earnings. Although free cash flow covers it, this could pressure the dividend if earnings decline.
- Underperformance vs. Market: OHI's 1-year return of 10.03% lags the S&P 500's 20.48% gain. Relative strength is negative across all timeframes (1m: -10.35%, 3m: -5.38%, 6m: -10.98%), indicating persistent underperformance.
- Interest Rate Sensitivity: As a REIT, OHI is highly sensitive to interest rates. With a beta of 0.582, it is less volatile, but rising rates increase borrowing costs and discount rates, pressuring valuations. Recent downgrades from Barclays and BofA highlight this risk.
- Valuation at Premium to History: The trailing P/E of 21.95x is near the middle of its 5-year range, but the forward P/E of 22.80x suggests no earnings growth expected. The PEG ratio of 0.77 is low, but the stock trades at a premium to its historical average P/E of around 15x.
OHI Technical Analysis
Omega Healthcare Investors (OHI) has been in a broad uptrend over the past year, with the stock up 10.03% over the last 12 months, though it has underperformed the S&P 500's 20.48% gain. The current price of $46.61 sits at 78.4% of its 52-week range (low of $39.26, high of $52.39), indicating the stock is closer to its highs than its lows, suggesting moderate bullish momentum but not overextension. The stock's beta of 0.582 indicates it is significantly less volatile than the broader market, which may appeal to risk-averse investors.
Beta
0.58
0.58x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$39-$52
Price range past year
Annual Return
+10.0%
Cumulative gain past year
| Period | OHI Return | S&P 500 |
|---|---|---|
| 1m | -7.9% | +3.6% |
| 3m | -2.7% | +2.7% |
| 6m | +0.1% | +11.4% |
| 1y | +10.0% | +18.7% |
| ytd | +4.7% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OHI Fundamental Analysis
Omega's revenue has been growing strongly, with Q1 2026 revenue of $322.96 million, up 16.68% year-over-year, and the company has consistently increased revenue from $252.75 million in Q2 2024 to $322.96 million in Q1 2026. The growth is driven by acquisitions and rent escalations, as evidenced by the revenue segments showing $71.16 million from issuer and subsidiary guarantors and $13.35 million from non-guarantor subsidiaries. The company's profitability is robust, with a net income of $151.05 million in Q1 2026, representing a net margin of 46.77%, and a gross margin of 97.21%, which is typical for a net-lease REIT. However, the operating margin of 62.55% is slightly lower than the gross margin due to operating expenses, but still healthy. Omega's balance sheet is solid, with a debt-to-equity ratio of 0.82 and a current ratio of 3.46, indicating strong liquidity. The company generated $218.90 million in operating cash flow and $210.14 million in free cash flow in Q1 2026, which comfortably covers its dividend payments of $198.42 million, resulting in a payout ratio of 132.24% based on net income, but the free cash flow coverage is adequate.
Quarterly Revenue
$322955000.0B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
97.2%
Latest Quarter
Free Cash Flow
$907053000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OHI Overvalued?
Given that Omega has positive net income, I selected the P/E ratio as the primary valuation metric. The trailing P/E is 21.95x, while the forward P/E is 22.80x, indicating that the market expects earnings to remain relatively stable. The stock's P/E is in line with the industry average for healthcare REITs, which typically trade around 20-25x, so Omega is not significantly overvalued or undervalued. Compared to its own historical range, the current P/E of 21.95x is near the middle of its 5-year band, which has ranged from as low as 9.86x in Q1 2022 to as high as 52.84x in Q4 2021, suggesting that the current valuation is reasonable given the company's improved fundamentals.
PE
22.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks: OHI's dividend payout ratio of 132.24% based on net income is a red flag, indicating that earnings do not fully cover the dividend. While free cash flow of $210.14M in Q1 2026 covers the $198.42M dividend payment, any decline in cash flow could force a cut. The company's debt-to-equity ratio of 0.82 is manageable, but rising interest rates increase interest expenses (Q1 2026 interest expense was $49.76M), which could pressure margins. Revenue concentration in skilled nursing facilities makes the company vulnerable to changes in government reimbursement policies and labor shortages, which could impact operator profitability and rent collections.